Are Novavax, Inc.(NASDAQ:NVAX), Celgene Corporation(NASDAQ:CELG), and Gilead Sciences, Inc.(NASDAQ:GILD) Poised For Success In The Biotechnology Industry?

Posted by Saimoon October 24, 2014 0 Comment 726 views


New York, NY – GDP INSIDER  –  10/24/2014.

This article discusses three biotechnology stocks: Novavax, Inc.(NASDAQ:NVAX), Celgene Corporation(NASDAQ:CELG), and Gilead Sciences, Inc.(NASDAQ:GILD)

Novavax, Inc.(NASDAQ:NVAX) is a Maryland-based biotechnology company that focuses on developing recombinant protein nanoparticle vaccines and adjuvants. The company announced yesterday that it intends Senior Vice President of Research and Development, Gregory Glenn, will be presenting new immunogenicity for the RSV F vaccine clinical trials in Philadelphia, PA on Oct. 26th. Novavax, a company that is expected to release its next earnings report between Nov. 5th and Nov. 10th, has a market capitalization of $1.16 billion.

Will Novavax Have An Active Monday Morning? View Our Free NVAX Analysis.

Celgene Corporation(NASDAQ:CELG) traded for a new 52 week high of $100.91 during yesterday’s trading. The boost came after the New Jersey-based biotechnology company reported its third quarter financial results. The figures included a net product sales of $1,957 million for the third quarter, a 19% increase from the same period during the previous fiscal year. Celgene also saw its net income increase from $669 million to $806 million year-over-year for the third quarter.

Should You Be Excited By Celgene’s Financial Results? Receive A Free CELG Analysis.

Gilead Sciences, Inc.(NASDAQ:GILD) will be releasing its third quarter financial results at 4:05PM EST on Oct. 28th, 2014. At 4:30PM EST, the company will host a conference call to discuss the figures and provide a business update. Gilead Sciences is a California-based biopharmaceutical company that develops medicines for life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company announced that Health Canada had issued a Notice of Compliance for its Harvoni chronic hepatitis C treatment on Oct. 16th, 2014.

Should You Be Excited By Gilead Sciences’ Potential? Take A Look At Our Free GILD Analysis.

About HotStockGains

HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.

Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.


Write Your Comment